A(2) adenosine receptors regulate CFTR through PKA and PLA(2)

Area of Science:

• Cell Biology
• Molecular Physiology
• Respiratory Medicine

Background:

• Adenosine (Ado) is a key signaling molecule in various physiological processes.
• The cystic fibrosis transmembrane conductance regulator (CFTR) is a crucial ion channel implicated in cystic fibrosis.
• Understanding CFTR regulation is vital for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate the role of adenosine (Ado) in activating the cystic fibrosis transmembrane conductance regulator (CFTR).
• To elucidate the specific signaling pathways involved in Ado-mediated CFTR activation, including receptors and enzymes.
• To assess the potential of this pathway to modulate both wild-type and mutant CFTR function.

Main Methods:

• In vitro studies using various cell lines (Calu-3, IB-3-1, COS-7) and primary human airway cells.
• In vivo experiments utilizing wild-type and CFTR-deficient mice.
• Measurement of intracellular cAMP levels, halide efflux, and arachidonic acid release.
• Pharmacological inhibition of specific receptors (A(2B)) and enzymes (PLA(2), cPLA(2)).
• Expression studies involving wild-type, DeltaF508, and G551D mutant CFTR.

Main Results:

• A(2B) adenosine receptors were identified in airway cells and mediated Ado-induced cAMP elevation and protein kinase A-dependent halide efflux.
• Adenosine stimulated arachidonic acid release, and phospholipase A(2) (PLA(2)) inhibition blocked Ado-activated halide efflux, indicating PLA(2) involvement.
• Ado stimulated CFTR-dependent nasal chloride secretion in mice, sensitive to A(2) receptor and PLA(2) blockade.
• Adenosine activated halide efflux in cells expressing both wild-type and mutant CFTR (DeltaF508, G551D), with the latter requiring additional factors.

Conclusions:

• Phospholipase A(2) (PLA(2)) and protein kinase A (PKA) are essential components of A(2B) receptor-mediated activation of CFTR.
• This signaling pathway can enhance the activity of both wild-type and mutant forms of CFTR.
• Targeting this adenosine-mediated pathway presents a potential therapeutic avenue for cystic fibrosis and other CFTR-related disorders.